160 related articles for article (PubMed ID: 22676879)
1. Modelling antiviral treatment to prevent hepatitis C infection among people who inject drugs in Victoria, Australia.
Hellard ME; Jenkinson R; Higgs P; Stoové MA; Sacks-Davis R; Gold J; Hickman M; Vickerman P; Martin NK
Med J Aust; 2012 Jun; 196(10):638-41. PubMed ID: 22676879
[TBL] [Abstract][Full Text] [Related]
2. Change in treatment paradigm in people who previously injected drugs with chronic hepatitis C in the era of direct-acting antiviral therapy.
Wong GL; Chan HL; Loo CK; Hui YT; Fung JY; Cheung D; Chung C; Chim AM; Wong VW;
J Gastroenterol Hepatol; 2019 Sep; 34(9):1641-1647. PubMed ID: 30707777
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study.
Grebely J; Dalgard O; Cunningham EB; Hajarizadeh B; Foster GR; Bruggmann P; Conway B; Backmund M; Robaeys G; Swan T; Amin J; Marks PS; Quiene S; Applegate TL; Weltman M; Shaw D; Dunlop A; Hellard M; Bruneau J; Midgard H; Bourgeois S; Staehelin C; Dore GJ;
Int J Drug Policy; 2017 Sep; 47():177-186. PubMed ID: 28624134
[TBL] [Abstract][Full Text] [Related]
4. Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: The Australian Trial in Acute Hepatitis C.
Alavi M; Spelman T; Matthews GV; Haber PS; Day C; van Beek I; Walsh N; Yeung B; Bruneau J; Petoumenos K; Dolan K; Kaldor JM; Dore GJ; Hellard M; Grebely J;
Int J Drug Policy; 2015 Oct; 26(10):976-83. PubMed ID: 26115881
[TBL] [Abstract][Full Text] [Related]
5. Implementing and scaling up HCV treatment services for people who inject drugs and other high risk groups in Ukraine: An evaluation of programmatic and treatment outcomes.
Mazhnaya A; Meteliuk A; Barnard T; Zelenev A; Filippovych S; Altice FL
Int J Drug Policy; 2017 Sep; 47():187-195. PubMed ID: 28811159
[TBL] [Abstract][Full Text] [Related]
6. Evaluating the population impact of hepatitis C direct acting antiviral treatment as prevention for people who inject drugs (EPIToPe) - a natural experiment (protocol).
Hickman M; Dillon JF; Elliott L; De Angelis D; Vickerman P; Foster G; Donnan P; Eriksen A; Flowers P; Goldberg D; Hollingworth W; Ijaz S; Liddell D; Mandal S; Martin N; Beer LJZ; Drysdale K; Fraser H; Glass R; Graham L; Gunson RN; Hamilton E; Harris H; Harris M; Harris R; Heinsbroek E; Hope V; Horwood J; Inglis SK; Innes H; Lane A; Meadows J; McAuley A; Metcalfe C; Migchelsen S; Murray A; Myring G; Palmateer NE; Presanis A; Radley A; Ramsay M; Samartsidis P; Simmons R; Sinka K; Vojt G; Ward Z; Whiteley D; Yeung A; Hutchinson SJ
BMJ Open; 2019 Sep; 9(9):e029538. PubMed ID: 31551376
[TBL] [Abstract][Full Text] [Related]
7. Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe.
Fraser H; Martin NK; Brummer-Korvenkontio H; Carrieri P; Dalgard O; Dillon J; Goldberg D; Hutchinson S; Jauffret-Roustide M; Kåberg M; Matser AA; Matičič M; Midgard H; Mravcik V; Øvrehus A; Prins M; Reimer J; Robaeys G; Schulte B; van Santen DK; Zimmermann R; Vickerman P; Hickman M
J Hepatol; 2018 Mar; 68(3):402-411. PubMed ID: 29080808
[TBL] [Abstract][Full Text] [Related]
8. Assessing the cost-effectiveness of treating chronic hepatitis C virus in people who inject drugs in Australia.
Visconti AJ; Doyle JS; Weir A; Shiell AM; Hellard ME
J Gastroenterol Hepatol; 2013 Apr; 28(4):707-16. PubMed ID: 23173753
[TBL] [Abstract][Full Text] [Related]
9. HCV treatment rates and sustained viral response among people who inject drugs in seven UK sites: real world results and modelling of treatment impact.
Martin NK; Foster GR; Vilar J; Ryder S; Cramp ME; Gordon F; Dillon JF; Craine N; Busse H; Clements A; Hutchinson SJ; Ustianowski A; Ramsay M; Goldberg DJ; Irving W; Hope V; De Angelis D; Lyons M; Vickerman P; Hickman M
J Viral Hepat; 2015 Apr; 22(4):399-408. PubMed ID: 25288193
[TBL] [Abstract][Full Text] [Related]
10. Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE study.
Midgard H; Hajarizadeh B; Cunningham EB; Conway B; Backmund M; Bruggmann P; Bruneau J; Bourgeois S; Dunlop A; Foster GR; Hellard M; Robaeys G; Thurnheer MC; Weltman M; Amin J; Marks PS; Quiene S; Dore GJ; Dalgard O; Grebely J;
Int J Drug Policy; 2017 Sep; 47():230-238. PubMed ID: 28633998
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals.
Martin NK; Vickerman P; Grebely J; Hellard M; Hutchinson SJ; Lima VD; Foster GR; Dillon JF; Goldberg DJ; Dore GJ; Hickman M
Hepatology; 2013 Nov; 58(5):1598-609. PubMed ID: 23553643
[TBL] [Abstract][Full Text] [Related]
12. Is the end of chronic hepatitis C virus infection in sight?
McCaughan GW
Med J Aust; 2012 Jun; 196(10):614. PubMed ID: 22676864
[No Abstract] [Full Text] [Related]
13. Hepatitis C virus dynamics among intravenous drug users suggest that an annual treatment uptake above 10% would eliminate the disease by 2030.
Bruggmann P; Blach S; Deltenre P; Fehr J; Kouyos R; Lavanchy D; Müllhaupt B; Rauch A; Razavi H; Schmid P; Semela D; Stoeckle M; Negro F
Swiss Med Wkly; 2017; 147():w14543. PubMed ID: 29120012
[TBL] [Abstract][Full Text] [Related]
14. Successful treatment of chronic hepatitis C with triple therapy in an opioid agonist treatment program.
Litwin AH; Soloway IJ; Cockerham-Colas L; Reynoso S; Heo M; Tenore C; Roose RJ
Int J Drug Policy; 2015 Oct; 26(10):1014-9. PubMed ID: 26341685
[TBL] [Abstract][Full Text] [Related]
15. Treatment and primary prevention in people who inject drugs for chronic hepatitis C infection: is elimination possible in a high-prevalence setting?
Gountas I; Sypsa V; Anagnostou O; Martin N; Vickerman P; Kafetzopoulos E; Hatzakis A
Addiction; 2017 Jul; 112(7):1290-1299. PubMed ID: 28107585
[TBL] [Abstract][Full Text] [Related]
16. Community nurse-led initiation of antiviral therapy for chronic hepatitis C in people who inject drugs does not increase uptake of or adherence to treatment.
Lewis H; Kunkel J; Axten D; Dalton J; Gardner H; Tippett A; Wynne S; Wilkinson M; Foster GR
Eur J Gastroenterol Hepatol; 2016 Nov; 28(11):1258-63. PubMed ID: 27487966
[TBL] [Abstract][Full Text] [Related]
17. Direct acting antiviral-based treatment of hepatitis C virus infection among people who inject drugs in Georgia: A prospective cohort study.
Bouscaillou J; Kikvidze T; Butsashvili M; Labartkava K; Inaridze I; Etienne A; Le Pluart D; Kamkamidze G; Gamezardashvili A; Kharshiladze D; Avril E; Luhmann N
Int J Drug Policy; 2018 Dec; 62():104-111. PubMed ID: 30384026
[TBL] [Abstract][Full Text] [Related]
18. Declining prevalence of current HCV infection and increased treatment uptake among people who inject drugs: The ETHOS Engage study.
Valerio H; Alavi M; Conway A; Silk D; Treloar C; Martinello M; Milat A; Dunlop A; Murray C; Henderson C; Amin J; Read P; Marks P; Degenhardt L; Stevens A; Prain B; Hayllar J; Reid D; Montebello M; Wade A; Christmass M; Cock V; Dore GJ; Grebely J;
Int J Drug Policy; 2022 Jul; 105():103706. PubMed ID: 35533635
[TBL] [Abstract][Full Text] [Related]
19. Scaling-up HCV prevention and treatment interventions in rural United States-model projections for tackling an increasing epidemic.
Fraser H; Zibbell J; Hoerger T; Hariri S; Vellozzi C; Martin NK; Kral AH; Hickman M; Ward JW; Vickerman P
Addiction; 2018 Jan; 113(1):173-182. PubMed ID: 28734093
[TBL] [Abstract][Full Text] [Related]
20. What is the impact of a country-wide scale-up in antiviral therapy on the characteristics and sustained viral response rates of patients treated for hepatitis C?
McDonald SA; Innes HA; Hayes PC; Dillon JF; Mills PR; Goldberg DJ; Barclay S; Allen S; Fox R; Fraser A; Kennedy N; Bhattacharyya D; Hutchinson SJ
J Hepatol; 2015 Feb; 62(2):262-8. PubMed ID: 25195556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
